Phase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinoma.
Ren Z, Shao G, Shen J, Zhang L, Zhu X, Fang W, Sun G, Bai Y, Wu J, Liu L, Yuan Y, Zhang J, Li Z, Zhang L, Yin T, Wu J, Hou X, Yu H, Li J, Wang Q, Zhu J, Fan J; Serplulimab-HCC Investigators.
Ren Z, et al. Among authors: zhu j.
Cancer Immunol Immunother. 2025 Jan 3;74(2):69. doi: 10.1007/s00262-024-03917-w.
Cancer Immunol Immunother. 2025.
PMID: 39751879